HUE033482T2 - CDC7 inhibitorok - Google Patents
CDC7 inhibitorok Download PDFInfo
- Publication number
- HUE033482T2 HUE033482T2 HUE14712966A HUE14712966A HUE033482T2 HU E033482 T2 HUE033482 T2 HU E033482T2 HU E14712966 A HUE14712966 A HU E14712966A HU E14712966 A HUE14712966 A HU E14712966A HU E033482 T2 HUE033482 T2 HU E033482T2
- Authority
- HU
- Hungary
- Prior art keywords
- methyl
- pyrazol
- cancer
- fluoropyrimidin
- isoindolin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Claims (7)
- CDC? Intniniorok SzaOadakni igénypontok1. VegyUlet, nid y 1 -=t^|)izoÍT^gí|=m-~ 1-~o^;.y«^·' egy gyôgvâszalikïg okfogadható sója vagy hkiráija.
- 2. Az 1, igénypont veknii vegyülni, mely "vZ-öuoi'pn'mndm-4~íi í-ó-meíil-OAI 1 heira/ol-d-il íízoWoMíDCöp.: 3. A? 1 igeryp>mi .vet out \épület, md\ Η5ΊΊηοφη ,n.sdn>4-í l-ó-mattl-ó-OH p«a?^i-4“ 1}Μ^ο1ΐιΐ”:1-οη*;Ε^0^η0όΐ»®^ vagy egy gyógyászatiig elfogadható sója, 4. A 3, igénypont szerinti vegyidet. me!y 3ÎH-pirazoí~4~
- 5. Az !. igénypont szerinti 'vegyidet, mely 3H5't]uorpir)niidí?n4':l)-4k'meii!~6~(l H-pirazoI-4-il hzohfootin-l-on, S enantiomer, vagy egy gyógyászati lag elfogadható sója.
- 6. Az L igénypont szerinti vegyüld, mely 3 ~( 5 -fíuorpl rí m id info -11)-3 -meti 1-6-( 1 H-piraz.ol-4-ií}ixoindo!in-l -on. S enantiomer.
- 7. Az %%énypôni':MÂitápölet mely :D(5-tiuoipirÍTnidin-44l)4-®eÍtó-(ÜJ-pira®Íí4-·· II|lzöindölitC1 fo% vagy hidrátja. 8 A 7. igénypont szerinti yegyúfot ntsly eg?ikÄiy^ fontgsndilílvilíoiós speMrnrnában 32,77, vatandnr fo.4ó< ló>p4, séfod, 1IÇ1Ü es <0,1 j közül eI?Aagÿ több 2#A Ö.2 ItÄnel jelentkezni8 jeUemzó mafoüinnfok.
- 9. Gyógyászati kes/itmény. mely az 1-8. igénypontok bármelyike szerinti vegyületei és egy 8>ögyászátüag elfogadható hordozót, higítóanfapt v*gy »óaTiy«pt:«a'lmazv Hl Az b-8. igénypontok bármelyike szeánti vegyiket terápiában történő alkalmazásra, ll. Át HE, igénypontoi bármelyike szarinti vegyülei rák kezdésében történő alkalmazásra, 1.2·. A vegyülei a IP IgAwpobt szermti aikalmazásra, aboi a rák mellrák., pstotészefcrák, tööőrák., véghéMk, Imotaíofögiai rák és leukémia közül körül ki
- 13, A vegyület a 13. igénypont szerinti alkalmazásra, ahol arák végbélrák.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361782798P | 2013-03-14 | 2013-03-14 | |
| US201361789108P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE033482T2 true HUE033482T2 (hu) | 2017-12-28 |
Family
ID=50382704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE14712966A HUE033482T2 (hu) | 2013-03-14 | 2014-03-07 | CDC7 inhibitorok |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US9156824B2 (hu) |
| EP (1) | EP2970221B1 (hu) |
| JP (1) | JP6064079B2 (hu) |
| KR (1) | KR101718645B1 (hu) |
| CN (1) | CN105008351B (hu) |
| AP (1) | AP2015008734A0 (hu) |
| AU (1) | AU2014228374B2 (hu) |
| BR (1) | BR112015020466B1 (hu) |
| CA (1) | CA2900773C (hu) |
| CL (1) | CL2015002530A1 (hu) |
| CR (1) | CR20150416A (hu) |
| CY (1) | CY1119199T1 (hu) |
| DK (1) | DK2970221T3 (hu) |
| EA (1) | EA027012B1 (hu) |
| ES (1) | ES2639793T3 (hu) |
| GT (1) | GT201500263A (hu) |
| HK (1) | HK1212696A1 (hu) |
| HR (1) | HRP20171151T1 (hu) |
| HU (1) | HUE033482T2 (hu) |
| IL (1) | IL240962B (hu) |
| JO (1) | JO3383B1 (hu) |
| LT (1) | LT2970221T (hu) |
| ME (1) | ME02805B (hu) |
| MX (1) | MX363438B (hu) |
| MY (1) | MY188145A (hu) |
| NZ (1) | NZ710392A (hu) |
| PE (1) | PE20151654A1 (hu) |
| PH (1) | PH12015502091B1 (hu) |
| PL (1) | PL2970221T3 (hu) |
| PT (1) | PT2970221T (hu) |
| RS (1) | RS56122B1 (hu) |
| SG (1) | SG11201507541PA (hu) |
| SI (1) | SI2970221T1 (hu) |
| TN (1) | TN2015000349A1 (hu) |
| TW (1) | TWI622396B (hu) |
| UA (1) | UA116125C2 (hu) |
| WO (1) | WO2014143601A1 (hu) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2615743T3 (es) * | 2012-10-15 | 2017-06-08 | Pfizer Ireland Pharmaceuticals | Procedimiento de preparación de voriconazol y análogos de los mismos |
| CA2897200C (en) | 2013-01-14 | 2021-07-06 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| CN108715590B (zh) | 2013-01-15 | 2022-03-08 | 因赛特公司 | 可用作pim激酶抑制剂的噻唑甲酰胺和吡啶甲酰胺化合物 |
| TWI627174B (zh) | 2013-03-14 | 2018-06-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調控劑 |
| EP2970271B1 (en) | 2013-03-14 | 2017-11-08 | Janssen Pharmaceutica NV | P2x7 modulators |
| EP2970304B1 (en) | 2013-03-14 | 2018-08-15 | Janssen Pharmaceutica NV | P2x7 modulators |
| KR102295740B1 (ko) | 2013-03-14 | 2021-09-01 | 베링거 인겔하임 인터내셔날 게엠베하 | 카텝신 c의 억제제로서 치환된 2-아자-바이사이클로[2.2.1]헵탄-3-카복실산(벤질-시아노-메틸)-아미드 |
| JO3773B1 (ar) | 2013-03-14 | 2021-01-31 | Janssen Pharmaceutica Nv | معدلات p2x7 |
| EP3036238A1 (en) | 2013-08-23 | 2016-06-29 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US10150766B2 (en) | 2014-09-12 | 2018-12-11 | Janssen Pharmaceutica Nv | P2X7 modulators |
| PL3191487T3 (pl) | 2014-09-12 | 2020-03-31 | Boehringer Ingelheim International Gmbh | Spirocykliczne inhibitory katepsyny C |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| TW201718546A (zh) | 2015-10-02 | 2017-06-01 | 英塞特公司 | 適用作pim激酶抑制劑之雜環化合物 |
| ES2845048T3 (es) * | 2016-09-22 | 2021-07-23 | Cancer Research Tech Ltd | Preparación y usos de derivados de pirimidinona |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| CN108383771A (zh) * | 2018-01-08 | 2018-08-10 | 华东师范大学 | 手性3,3-二取代异吲哚啉-1-酮衍生物及其合成方法和应用 |
| GB201807147D0 (en) | 2018-05-01 | 2018-06-13 | Oncologica Uk Ltd | Therapeutic combination |
| NL2021185B1 (en) | 2018-06-26 | 2020-01-06 | Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis | Combination Therapy and Use Thereof for Treating Cancer |
| WO2020065614A1 (en) | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
| EP3856178A1 (en) | 2018-09-28 | 2021-08-04 | Janssen Pharmaceutica NV | Monoacylglycerol lipase modulators |
| US20220220125A1 (en) * | 2019-04-16 | 2022-07-14 | Janssen Pharmaceutica Nv | Fused isoindolin-1-one derivatives useful as grk2 inhibitors |
| WO2021064569A1 (en) | 2019-09-30 | 2021-04-08 | Janssen Pharmaceutica Nv | Radiolabelled mgl pet ligands |
| AU2021241879A1 (en) | 2020-03-26 | 2022-09-29 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0400970D0 (sv) * | 2004-04-14 | 2004-04-14 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| US7576082B2 (en) * | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
| TW200833695A (en) * | 2006-10-12 | 2008-08-16 | Xenon Pharmaceuticals Inc | Use of spiro-oxindole compounds as therapeutic agents |
| JP5451602B2 (ja) * | 2007-06-08 | 2014-03-26 | アッヴィ・インコーポレイテッド | キナーゼ阻害薬としての５−ヘテロアリール置換インダゾール類 |
| US8648069B2 (en) * | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
-
2014
- 2014-03-04 JO JOP/2014/0067A patent/JO3383B1/ar active
- 2014-03-05 TW TW103107546A patent/TWI622396B/zh active
- 2014-03-07 UA UAA201508675A patent/UA116125C2/uk unknown
- 2014-03-07 ME MEP-2017-173A patent/ME02805B/me unknown
- 2014-03-07 SG SG11201507541PA patent/SG11201507541PA/en unknown
- 2014-03-07 HU HUE14712966A patent/HUE033482T2/hu unknown
- 2014-03-07 KR KR1020157024644A patent/KR101718645B1/ko not_active Application Discontinuation
- 2014-03-07 AU AU2014228374A patent/AU2014228374B2/en active Active
- 2014-03-07 BR BR112015020466-0A patent/BR112015020466B1/pt active IP Right Grant
- 2014-03-07 LT LTEP14712966.2T patent/LT2970221T/lt unknown
- 2014-03-07 MY MYPI2015703062A patent/MY188145A/en unknown
- 2014-03-07 WO PCT/US2014/021466 patent/WO2014143601A1/en active Application Filing
- 2014-03-07 US US14/200,141 patent/US9156824B2/en active Active
- 2014-03-07 NZ NZ710392A patent/NZ710392A/en unknown
- 2014-03-07 CN CN201480011202.4A patent/CN105008351B/zh active Active
- 2014-03-07 PE PE2015001925A patent/PE20151654A1/es active IP Right Grant
- 2014-03-07 ES ES14712966.2T patent/ES2639793T3/es active Active
- 2014-03-07 SI SI201430280T patent/SI2970221T1/sl unknown
- 2014-03-07 DK DK14712966.2T patent/DK2970221T3/en active
- 2014-03-07 EP EP14712966.2A patent/EP2970221B1/en active Active
- 2014-03-07 EA EA201591509A patent/EA027012B1/ru not_active IP Right Cessation
- 2014-03-07 RS RS20170791A patent/RS56122B1/sr unknown
- 2014-03-07 CA CA2900773A patent/CA2900773C/en active Active
- 2014-03-07 MX MX2015012583A patent/MX363438B/es unknown
- 2014-03-07 JP JP2016500764A patent/JP6064079B2/ja active Active
- 2014-03-07 PT PT147129662T patent/PT2970221T/pt unknown
- 2014-03-07 AP AP2015008734A patent/AP2015008734A0/xx unknown
- 2014-03-07 PL PL14712966T patent/PL2970221T3/pl unknown
-
2015
- 2015-08-12 TN TN2015000349A patent/TN2015000349A1/en unknown
- 2015-08-14 CR CR20150416A patent/CR20150416A/es unknown
- 2015-08-31 IL IL240962A patent/IL240962B/en active IP Right Grant
- 2015-09-09 CL CL2015002530A patent/CL2015002530A1/es unknown
- 2015-09-09 GT GT201500263A patent/GT201500263A/es unknown
- 2015-09-14 PH PH12015502091A patent/PH12015502091B1/en unknown
-
2016
- 2016-01-21 HK HK16100636.2A patent/HK1212696A1/zh unknown
-
2017
- 2017-07-27 HR HRP20171151TT patent/HRP20171151T1/hr unknown
- 2017-08-10 CY CY20171100861T patent/CY1119199T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2970221T3 (en) | CDC7 INHIBITORS | |
| JP7073316B2 (ja) | 癌の治療のためのｅｒｂｂチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体 | |
| JP6869947B2 (ja) | 置換キナゾリン化合物ならびにそのｇ１２ｃ変異ｋｒａｓ、ｈｒａｓおよび／またはｎｒａｓタンパク質の阻害剤としての使用 | |
| RU2692766C1 (ru) | Пролекарства пиридонамидов, применяемые в качестве модуляторов натриевых каналов | |
| RU2683788C2 (ru) | Амиды хинолина и хиназолина, полезные в качестве модуляторов натриевых каналов | |
| JP6794609B2 (ja) | チェックポイントキナーゼ１（ｃｈｋ１）阻害剤として有用な３，５−二置換ピラゾール、並びにその調製及び用途 | |
| CN109563100A (zh) | 三唑并嘧啶化合物的晶体形式 | |
| HUE034568T2 (hu) | Kinazolin-inhibitorok epidermális növekedési faktor-receptorok mutáns formáinak aktiválásának gátlására | |
| AU2018234985B2 (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| BR112017007239B1 (pt) | Inibidor da aurora a cinase, seus usos, e composição farmacêutica". | |
| US10501466B2 (en) | WDR5 inhibitors and modulators | |
| JP2019116491A (ja) | １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オンの固体形態、その組成物、及びそれらの使用方法 | |
| CN110066272B (zh) | 取代的苯并[d]咪唑类化合物及其药物组合物 | |
| EP3331873B1 (en) | A 4-(3-pyrazolylamino)-benzimidazole derivative as jak1 inhibitor for treating cancer | |
| BR112018075086B1 (pt) | Derivados de pirazolilaminobenzimidazol, seu uso, e composição farmacêutica | |
| KR20130093140A (ko) | 옥사졸로[5,4-b]피리딘-5-일 화합물 및 암의 치료를 위한 그의 용도 | |
| CN115286645A (zh) | 三环杂环衍生物及其药物组合物和用途 | |
| JP2024522184A (ja) | Ｓｅｔｄ２阻害剤との併用療法 | |
| EP4161910A1 (en) | 2-(3-(2-methyl-6-(p-tolyl) pyridine-3-yl) ureido) benzenesulfonamide and derivatives as inhibitor of carbonic anhydrase ix for the treatment of cancer | |
| CN113861195A (zh) | 一种多稠环egfr抑制剂及其制备方法和应用 |